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Abstract
Noroviruses (NoVs) are a leading cause of acute gastroenteritis outbreaks and sporadic cases of 
diarrhea in industrialized countries. To study the prevalence and genetic diversity of NoVs in 
Guatemala, stool specimens were collected from hospitalized and ambulatory patients presenting 
with diarrhea (≥3 loose or liquid stools in a 24-hr period) who were enrolled in a prospective 
surveillance system in the Departments of Santa Rosa (October 2007 to August 2010) and 
Quetzaltenango (August 2009 to August 2010), Guatemala. Specimens were tested for rotavirus, 
enteric bacteria, and parasites by routine methods and for genogroups I and II NoV by real-time 
reverse transcription-PCR. A total of 2,403 stool specimens were collected from hospitalized (n = 
528) and ambulatory patients (n = 1,875). Overall, 341 (14%) samples tested positive for NoVs 
including 114 (22%) hospitalized and 227 (12%) ambulatory patients. NoVs disease peaked 
during the winter (November–January) months. Among the 341 NoVs-positive patients, 32 (9%) 
were also positive for rotavirus, 32 (9%) for bacteria, and 9 (3%) for protozoa. Nucleotide 
sequences were obtained from 84 samples collected from hospitalized children aged <5 years of 
age, which could be grouped into nine GII and three GI genotypes with GII.4 (74%) and GI.8 
(10%) being the most common. This is the first study on the prevalence of NoVs among 
hospitalized and ambulatory patients with diarrhea in Guatemala. The findings highlight the need 
to implement laboratory diagnostics for NoVs to improve appropriate clinical management of 
diarrheal diseases and guide vaccine development.
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INTRODUCTION
Noroviruses (NoVs) are the leading cause of acute infectious diarrhea and gastroenteritis 
outbreaks worldwide [Glass et al., 2009]. In developing countries, NoVs are estimated to 
cause 200,000 deaths each year among children aged <5 years [Patel et al., 2009]. In Latin 
America data on NoVs are limited, but recent studies suggest they could be important 
contributors to severe diarrheal disease in children as well as a significant cause of traveler’s 
diarrhea [Chapin et al., 2005; Bucardo et al., 2008; Gutiérrez-Escolano et al., 2010; Koo et 
al., 2010; O’Ryan et al., 2010].
NoVs are members of the genus Norovirus within the family Caliciviridae. They can be 
subdivided genetically into five genogroups (G) of which GI, GII, and GIV are associated 
with infection in humans [Glass et al., 2009]. In the last decade, GII.4 viruses have emerged 
as the predominant genotype worldwide responsible for the majority of outbreaks and 
sporadic cases of norovirus gastroenteritis [Medici et al., 2006; Siebenga et al., 2009; 
Ferreira et al., 2010; Dai et al., 2011].
There is limited understanding of the epidemiology of NoVs in developing countries, as 
laboratory diagnosis is not widely available. NoVs are non-cultivable in vitro and, before the 
1990s, virus detection depended on demonstration of characteristic viral particles in clinical 
specimens using electron microscopy. In recent years, the availability of molecular methods 
such as real-time reverse transcription-polymerase chain reaction (RT-qPCR) and sequence-
based typing has allowed a better understanding of the molecular epidemiology of NoVs in 
developed countries [Vega et al., 2011]. RT-qPCR offers increased sensitivity and 
specificity with a low risk of cross-contamination, but this capacity is expensive and may 
not be available in most laboratories in developing countries.
In Guatemala, as in many other countries in Central America, diarrhea is one of the most 
common causes of morbidity and mortality in children [Bryce et al., 2005], yet little is 
known about the etiologic role of NoVs. The U.S. Centers for Disease Control and 
Prevention (CDC), in collaboration with the Guatemalan Ministry of Public Health and 
Welfare and the University of the Valley of Guatemala (UVG), conducted active facility-
based surveillance for diarrheal, respiratory, febrile, and acute infectious neurological 
diseases in two sites in Guatemala starting in 2007. The present report describes the 
laboratory-based detection of NoVs among hospitalized and ambulatory patients with 
diarrhea enrolled in this surveillance system.
MATERIALS AND METHODS
Study Sites
Guatemala is divided into 23 administrative departments. The surveillance data described in 
this report were collected in the departments of Santa Rosa and Quetzaltenango. The 
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Department of Santa Rosa, located south of Guatemala City, has a population of 308,522 
(65% rural and 35% urban) in an area of 3,164 km2. Approximately 97% of the population 
is mixed European and Amerindian ancestry. Health facilities participating in this study site 
include Cuilapa Regional Hospital, which serves the entire department, the health center and 
five health posts that serve the municipality of Nueva Santa Rosa. The Department of 
Quetzaltenango, located west of Guatemala City, has a population of 780,000 in an area of 
2,132 km2, of which 54% are Amerindian indigenous. Health facilities participating in this 
study site include the Hospital of the Western Region, which serves the entire department, 
and four health centers (Cantel, Concepción, La Esperanza, and Xecam). A prospective 
surveillance system with integrated laboratory diagnostics for diarrhea, respiratory disease 
and unspecified febrile illness was established in Santa Rosa in July 2007 and in 
Quetzaltenango in February 2009.
Study Patients
An attempt was made to enroll patients of all ages presenting to the surveillance facilities 
with acute diarrhea, defined as ≥3 liquid stools in a 24-hr period that began during the seven 
days before presentation. Those who met the case definition and consented were enrolled in 
the study. For this analysis, we included all patients enrolled from October 2007 to August 
2010 in Santa Rosa since the system became fully functional at both hospitalized and 
ambulatory settings starting in October, and from August 2009 to August 2010 in 
Quetzaltenango. Of 4,064 eligible diarrhea patients, 3,794 (93%) were enrolled in 
surveillance, of which 2,567 (68%) provided a stool specimens, of which 2,403 (94%) were 
tested for norovirus and included in the final analysis. Among the 4,064 eligible patients, the 
median age was 2 years (range: 1 day to 91 years), with 66% of patients aged <5 years. 
Likewise, among the 2,403 patients included in the study, the median age was 2 years 
(range: 1 day to 91 years), with 61% of patients aged <5 years.
Specimen Collection and Processing
Samples of stool obtained by rectal swab were placed in Cary–Blair medium and transported 
along with bulk whole stool samples at 4°C within 24 hr of collection, to the laboratories at 
the respective study site hospitals for initial processing. A commercial qualitative EIA was 
used for the detection of rotavirus (Group A; IDEIA Rotavirus test kits, Dako, Ely, UK). 
Microbiologic testing included cultures to detect Salmonella spp., Shigella spp., and 
Campylobacter spp. and microscopic examination to study parasitic pathogens. Stool 
aliquots were then sent to the UVG laboratories and tested for NoVs by RT-qPCR [Trujillo 
et al., 2006]. After centrifugation at 6,000 × g for 5 min at 4°C, viral RNA was extracted 
from 20% clarified stool suspension by using QIAamp Viral RNA Kit (QIAGEN, Hilden, 
Germany) according to the manufacturer’s instructions. A total of 60 μl of purified viral 
RNA was obtained and stored at −70°C until RT-qPCR analysis.
TaqMan Real-Time RT-PCR
Molecular testing for NoVs was performed as described previously [Vega et al., 2011]. All 
sets of primers and probes were commercially manufactured (Integrated DNA Technologies, 
San Diego, CA). For each sample, monoplex RT-qPCR reactions were performed for NoV 
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GI and GII as well as for ribonucleoprotein (RNP) included as an internal control, by using 
the AgPath-ID One-Step RT-PCR Kit (Applied Biosystems, Foster City, CA) on a 7500 
Realtime PCR platform (Applied Biosystems). The amplification of NoV GI was conducted 
using the primer set Cog 1F/Cog 1R and TaqMan probe Ring 1C [Vega et al., 2011], while 
NoV GII detection was performed using primer set Cog 2F/Cog 1R and TaqMan probe 
Ring2 as previously reported [Vega et al., 2011]. The final reaction mix of 25 μl consisted of 
0.4 μM of each oligonucleotide primer and 0.2 μM of TaqMan Probe. Cycling conditions 
included reverse transcription for 10 min at 45°C and denaturation for 10 min at 95°C, 
followed by 45 cycles of 15 sec at 95°C and 1 min at 60°C. RNP amplification included the 
sense primer RNP F (5′-AGATTTGGACCTGC-GAGCG-3′), antisense primer RNP R (5′-
GAGCGG-CTGTCTCCACAAGT-3′) and TaqMan probe RNP (5′-FAM-
TTCTGACCTGAAGGCTCTGCGCG-BHQ-3′). The final reaction mix of 25 μl consisted 
of 5 μl of the target RNA, 0.30 μM of each primer, 0.10 μM of the probe and water. The 
RNA was reverse transcribed for 10 min at 45°C followed by 10 min at 95°C and 45 cycles 
of 15 sec at 95°C, and 1 min at 55°C. Any sample crossing the threshold before cycle 
threshold (Ct) value of 40 was considered positive.
Sequencing Analysis
Ninety-two NoV positive stool specimens from hospitalized children less than 5 years of age 
were tested by conventional RT-PCR followed by sequence analysis. All specimens were 
amplified by conventional RT-PCR for region D [Vinjé et al., 2004] and region D negative 
samples were amplified for region C [Kojima et al., 2002]. Samples negative for both region 
C and region D were classified as untypeable. Amplicons were cleaned up by using the QIA 
Quick Gel Extraction Kit (Qiagen, Valencia, CA) according to the instructions from the 
manufacturer. Purified DNA was cycle sequenced bi-directionally with Big Dye v1.1 
(Applied Biosystems, CA). Cycle sequence clean up was performed with Big Dye 
Xterminator (Applied Biosystems) and sequenced on a 3130XL Sequencer. Sequences were 
analyzed on Sequencher 4.7 (Gene Codes, Ann Arbor, MI), BioEdit 7.0 (http://
www.mbio.ncsu.edu/BioEdit/bioedit.html), and phylogenetic analysis done with TreeCon 
1.3b (TreeCon, Konstanz, Germany).
Data Analysis
Data were entered during patient interviews using handheld devices. Statistical (Chi-square 
test, two-sided P-value <0.05 considered significant) and descriptive analyses were 
performed using SAS v9.2 (SAS Institute, Cary, NC) and Epi Info v3.4.3 (CDC, Atlanta, 
GA).
Ethics
All patients ≥18 years of age were asked for verbal consent for screening and, if they met 
the case definition, written, informed consent to participate in the surveillance study. Care 
providers of children <18 years old were asked for verbal consent to screen their child to 
determine eligibility, after which written, informed consent was requested from the parents 
or guardians and written, informed assent from children aged 7 to 17 years old. The study 
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was approved by the Institutional Review Board of the CDC and the UVG (Guatemala City, 
Guatemala), and by the Guatemalan Ministry of Health and Welfare.
RESULTS
Of 4,064 patients with acute diarrhea that were eligible for participation from Santa Rosa 
(October 2007 to August 2010) and Quetzaltenango (August 2009 to August 2010), 2,403 
(59%) were enrolled and had stool specimens tested for NoVs. Of these, 528 (22%) were 
hospitalized patients and 1,875 (78%) were from ambulatory clinics. Viral agents were the 
most frequently identified pathogens among both ambulatory (21%, 385) and hospitalized 
(49%, 259) patients. NoV was the most common pathogen detected in ambulatory patients 
(12%), followed by rotavirus (9%), whereas in hospitalized patients, rotavirus was detected 
most frequently (31%), followed by NoVs (22%; Table I). No etiologic agents were 
identified in 66% of ambulatory patients and 45% of hospitalized patients.
NoV was detected in samples from 341 (14%) patients with diarrhea. The highest number of 
cases occurred during the colder months of the year (November–January), immediately 
following the rainy season (Fig. 1). The proportion of stools positive for NoVs during 
November–January (23%) was significantly higher than that during the other months of the 
year (11%; P < 0.0001).
Among the 341 NoV-positive specimens, 281 (84%) tested positive for GII and 53 (18%) 
for GI, with both genogroups detected in seven (2%) specimens. Mixed infections of 
norovirus and other enteric pathogens were found in 73 samples, including 32 (9%) 
specimens positive for rotavirus, 32 (9%) positive for enteric bacteria, and 9 (3%) positive 
for protozoa (Fig. 2). There was no correlation between coinfection with other diarrhea 
pathogens and Ct value from a NoV-positive sample.
Ninety-two NoV-positive specimens were selected randomly for further sequencing analysis 
including 16 GI positive specimens, 72 GII positive specimens, and four specimens that 
were positive for both GI and GII. Eight (8.7%) samples tested negative for both regions C 
and D (Table II) and nucleotide sequence analysis of the remaining 84 NoV-positive 
samples (region D [n = 72] and region C [n = 12]) showed that the most commonly 
identified genotype was GII.4 Minerva (74%) followed by GI.8 (10%), GII.6 (4%), GII.2 
(2%), GII.3 (2%), GII.14 (2%), GI.7 (2%), GI.3 (2%), and GII.13 (1%).
DISCUSSION
This is the first laboratory-based study on the prevalence of NoVs in sporadic cases of 
diarrhea in Guatemala. The results showed that NoV is one of the leading etiologic agents of 
acute diarrhea among patients seeking care in Guatemala, with an overall prevalence of 
14%, very similar to rotavirus. The greater detection rate of NoVs among hospitalized 
versus ambulatory patients (22% vs. 12%) underscores further the public health importance 
of NoV disease.
The NoV prevalence falls within the range reported in other developed and developing 
countries. Prevalence of severe diarrhea attributable to NoVs reported in other studies 
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ranged from 3% in South Africa and Australia to up to 31% in Peru [Patel et al., 2008]. In 
children with mild and moderate diarrhea, estimates ranged from 5.5% in Chile to 36% in 
England [Patel et al., 2008]. Interestingly, Nicaragua has reported a similar prevalence 
within a pediatric population suggesting that NoVs are a common cause of diarrhea in the 
Central American region [Bucardo et al., 2008].
NoV was not only the most frequently detected etiological agent in specimens from 
ambulatory patients, but the virus was, after rotavirus, also the second leading cause of 
diarrhea requiring hospitalization. Other relevant non-viral enteric pathogens, such as 
bacteria and protozoa, exhibited lower rates of infections and were found as co-infecting 
agents in 12% of NoVs-positive samples. In addition, the first laboratory confirmed NoV 
outbreak in a Guatemala was reported recently [Arvelo et al., 2012] further highlighting the 
importance of NoVs as a diarrheal pathogen in developing countries.
Sequence analysis of NoV strains in the hospitalized children showed co-circulation of 12 
different genotypes. However, GII.4 Minerva was the most common genotype, accounting 
for approximately three-fourths of the strains. Worldwide, GII.4 is responsible for at least 
62% of all NoVs outbreaks [Siebenga et al., 2009] and has also caused multiple NoVs 
pandemics in the last decade [Bull et al., 2006; Tu et al., 2008; Siebenga et al., 2009]. An 
experimental vaccine has recently demonstrated proof of concept that NoV illness can be 
prevented [Atmar et al., 2011], and thus data on the distribution of specific NoVs genotypes 
in Guatemala and other Latin American countries is critical to guide the development of 
candidate vaccines effective for the region.
This study has several limitations. First, no parallel enrollment of control patients was 
performed, so we cannot be certain that detection of NoV was causally associated with 
illness in all patients. However, we have tested a subset of 60 fecal specimens from healthy 
children <5 years of age from the Department of Santa Rosa who did not report diarrhea 
within the 2 weeks preceding interview, and found that only 5% were NoVs GII positive, 
supporting the etiologic role of NoVs when detected in diarrhea patients (unpublished data). 
Viral load has been used previously to help discriminate etiologic versus incidental detection 
of NoV in a fecal sample [Phillips et al., 2009]. Although standard curves using quantified 
RNA transcripts were not included in the assays and therefore the viral load could not be 
quantified for each sample, 81% of the NoV positive samples had Ct values lower than 36 
suggesting that the majority of the diarrheal illness within the study population could be 
reasonably ascribed to NoVs infection when detected.
In conclusion, this study demonstrates that NoVs are a major etiologic agent of diarrheal 
disease in Guatemala. These findings highlight the importance of implementing NoVs 
diagnostics to assess NoV disease trends and genetic strain diversity over time. This 
information will not only impact future therapeutic and preventative strategies targeting 
NoVs infections in Guatemala, but will also be critical in guiding the development and 
introduction of NoVs vaccines as well as monitoring their subsequent impact.
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Monthly distribution of NoVs infection among stool specimens submitted from diarrhea 
patients, Santa Rosa, Guatemala (Oct 2007 to Aug 2010). *Proportion positive for NoVs 
(%) was calculated as a function of total number of stool samples tested.
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Coinfections in patients positive for norovirus. *Percent based on 341 patients positive for 
norovirus. **Includes Campylobacter spp., Shigella spp., and Salmonella spp. ***Includes 
Giardia lamblia and Cryptosporidium parvum.
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TABLE II
Norovirus Genotypes Detected Among Hospitalized Children Aged <5 Years in Guatemala; (−) Not Tested
ORF2 gene
Region D Region C Total
Genogroup I (GI) n = 12 n = 12
 GI.8 8 — 8
 GI.3 2 — 2
 GI.7 2 — 2
Genogroup II (GII) n = 63 n = 9 n = 72
 GII.4 Minerva (2006b) 47 1 48
 GII.4 Riviera (Osaka) 9 — 9
 GII.4 Yerseke (2006a) 2 3 5
 GII.6 2 1 3
 GII.3 2 — 2
 GII.2 1 1 2
 GII.14 — 2 2
 GII.13 — 1 1
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